Responsive neurostimulation (RNS) is a new method of controlling seizures by delivering electrical stimulation to the seizure focus from a small implanted device. Designed by Neuropace in Mountain View, CA, this is the first and only device that monitors and responds to brain activity. The RNS device received FDA approval in 2013. It is considered an adjunctive therapy for patients with drug-resistant epilepsy who are not surgical candidates, or who have already failed surgery other types of surgery such as the VNS.
The system comes with a remote monitor that patients use at home to wirelessly collect information from the neurostimulator and then transfer it to a patient data management system. The patient’s neurologist can log into this system at any time to review seizure activity. This helps physicians learn more about their patients’ seizures and improves patient care.
In clinical trials, patients treated with this device experienced substantial seizure reductions in the first year and continued to improve over time. During a controlled study, 230 patients with RNS were followed over time. The average decrease in seizures was 44% after 1 year, 53% at 2 years, and up to 66% after 3 to 6 years of using RNS.